{"id":"NCT01057693","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","briefTitle":"Study Of Pregabalin (Lyrica) In Patients With Painful Diabetic Peripheral Neuropathy","officialTitle":"A PHASE 3B MULTICENTER, DOUBLE-BLIND, RANDOMIZED WITHDRAWAL EFFICACY AND SAFETY STUDY OF PREGABALIN IN THE TREATMENT OF PATIENTS WITH INADEQUATELY TREATED PAINFUL DIABETIC PERIPHERAL NEUROPATHY","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-03-31","primaryCompletion":"2012-01-30","completion":"2012-01-30","firstPosted":"2010-01-27","resultsPosted":"2013-02-22","lastUpdate":"2021-01-20"},"enrollment":633,"design":{"allocation":"RANDOMIZED","model":null,"masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Neuropathy, Painful"],"interventions":[{"type":"DRUG","name":"pregabalin (Lyrica)","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"pregabalin (Lyrica)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"Patients will be switched from their current medication for painful diabetic peripheral neuropathy to evaluate the safety and efficacy of pregabalin as compared to placebo. All patients will receive pregabalin, and half of patients will receive placebo at some point during the study.","primaryOutcome":{"measure":"Change From Single-Blind Baseline in Mean Pain Score at Week 19 During Double-Blind Phase","timeFrame":"SB Baseline, Week 19 (DB Phase)","effectByArm":[{"arm":"Pregabalin DB","deltaMin":6.8,"sd":1.24},{"arm":"Placebo","deltaMin":6.7,"sd":1.32}],"pValues":[{"comp":"OG000 vs OG001","p":"0.1221"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":1},"locations":{"siteCount":172,"countries":["United States","Canada","Puerto Rico","South Africa"]},"refs":{"pmids":["23887339"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081242&StudyName=Study%20Of%20Pregabalin%20%28Lyrica%29%20In%20Patients%20With%20Painful%20Diabetic%20Peripheral%20Neuropathy"]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":665},"commonTop":["Oedema peripheral","Dizziness","Somnolence","Headache","Nausea"]}}